1. Dr. Diego A. Rodríguez MD, PhD.
Pulmonary Hypertension Unit and Pulmonary Embolism Response Team,
Pulmonology Department, Hospital del Mar, Barcelona.
darodriguez@psmar.cat
Novel biomarkers in pulmonary hypertension:
therapeutic implications nowadays?

2. SCHEMATIC DIAGRAM SHOWING DIFFERENT GROUPS OF BIOMARKERS
FOR PULMONARY HYPERTENSION

3. BIOMARKERS FOR A SAME DISEASE (?)
Eur Respir J 2012; 40: 596–603
Eur Respir J. 2019 Jan 24;53(1).

4. COMPARISON AMONG MAIN FEATURES OF BIOMARKERS
THAT MAY INFLUENCE THEIR USE IN CLINICAL PRACTICE

5. BIOMARKER CORRELATIONS WITH CLINICAL ENDPOINTS
AND PROGNOSIS IN PULMONARY HYPERTENSION
Biomarker signatures that might predict
favorable responses to therapies.
0
Am J Respir Cell Mol Biol Vol 52, Iss 6, pp 663–673, Jun 2015

6. TREATMENT-RELATED BIOMARKER CHANGES
IN PULMONARY HYPERTENSION
Am J Respir Cell Mol Biol Vol 52, Iss 6, pp 663–673, Jun 2015

7. CLINICAL TRIALS EVALUATING NT-PROBNP AS A BIOMARKER FOR
PULMONARY ARTERIAL HYPERTENSION COMBINATION THERAPY
Am J Cardiol 2017;120:S89–S95

8. BIOMARKERS (No, Thanks)
Eur Respir J. 2019 Jan 24;53(1)

9. RISK ASSESSMENT IN PULMONARY ARTERIAL HYPERTENSION
2015 ESC/ERS Guidelines

10. Risk assessment, prognosis and guideline implementation in
pulmonary arterial hypertension
Eur Respir J. 2017 Aug 3;50(2)
Kidney Function
Obesity
Age

11. THE BEST BIOMARKER !!!! (2019 “up-date”)
Eur Respir J 2018; 52: 1800497

12. THE BEST BIOMARKER !!!! (2019 “up-date”)
Advances in Pulmonary Hypertension Volume 16, Number 3; 2018

13. DYSPNEA, THE GREAT UNKNOWN ...
Eur Respir J. 2019 Jan 24;53(1).

14. Vasoregulatory mediators and/or biomarkers relevant to current pulmonary
arterial hypertension (PAH) therapy, and their interactions.
Am J Respir Cell Mol Biol Vol 52, Iss 6, pp 663–673, Jun 2015
Endothelial cells
vascular smooth muscle cells
Endogenous mediators Enzymes or other protein targets
Mediator-relevant drugs
(stimulatory)
Mediator-relevant drugs
(inhibitory])

15. CONCLUSIONS
• There is no single biomarker in PH that shows superiority in
predicting patient response.
• An integrative approach is necessary, using a combination of
biomarkers along with other clinical and paraclinical tests like
NYHA functional class and echocardiography.
• The identification of novel biomarker is urgently needed to help
optimize and individualize therapy.

16. Dr. Diego A. Rodríguez MD, PhD.
Pulmonary Hypertension Unit and Pulmonary Embolism Response Team,
Pulmonology Department, Hospital del Mar, Barcelona.
darodriguez@psmar.cat
Novel biomarkers in pulmonary hypertension:
therapeutic implications nowadays?